In non-small-cell lung cancer (NSCLC), the use of the AKT inhibitor MK-2206 in combination with erlotinib, an EGFR inhibitor, showed synergy between the two inhibitors [60]. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.